Insider Selling: CVRx (NASDAQ:CVRX) Major Shareholder Sells $22,132.00 in Stock

CVRx, Inc. (NASDAQ:CVRX) major shareholder & Johnson Johnson sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $10.06, for a total value of $22,132.00. Following the completion of the transaction, the insider owned 4,047,198 shares in the company, valued at approximately $40,714,811.88. This trade represents a 0.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

& Johnson Johnson also recently made the following trade(s):

• On Friday, November 21st, & Johnson Johnson sold 500 shares of CVRx stock. The shares were sold at an average price of $10.00, for a total value of $5,000.00.
• On Wednesday, November 12th, & Johnson Johnson sold 1,000 shares of CVRx stock. The stock was sold at an average price of $10.00, for a total transaction of $10,000.00.
• On Friday, November 7th, & Johnson Johnson sold 200 shares of CVRx stock. The stock was sold at an average price of $10.00, for a total transaction of $2,000.00.
• On Thursday, November 6th, & Johnson Johnson sold 52,332 shares of CVRx stock. The stock was sold at an average price of $10.21, for a total value of $534,309.72.

CVRx Price Performance

CVRx stock opened at $9.90 on Friday. The stock has a market cap of $259.35 million, a P/E ratio of -4.70 and a beta of 1.28. The company has a current ratio of 11.99, a quick ratio of 10.78 and a debt-to-equity ratio of 0.85. The company has a 50-day moving average price of $9.27 and a 200 day moving average price of $7.79. CVRx, Inc. has a 12-month low of $4.30 and a 12-month high of $18.55.

CVRx (NASDAQ:CVRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%.The company had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts anticipate that CVRx, Inc. will post -1.91 earnings per share for the current year.

Institutional Trading of CVRx

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Stoneridge Investment Partners LLC increased its position in CVRx by 7.9% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 20,126 shares of the company’s stock worth $162,000 after purchasing an additional 1,471 shares during the period. Alliancebernstein L.P. lifted its stake in shares of CVRx by 10.7% in the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after purchasing an additional 1,700 shares during the period. Cresset Asset Management LLC increased its holdings in CVRx by 3.5% in the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after buying an additional 1,823 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of CVRx by 13.0% in the 1st quarter. Rhumbline Advisers now owns 19,018 shares of the company’s stock worth $233,000 after acquiring an additional 2,192 shares during the period. Finally, Deutsche Bank AG boosted its position in CVRx by 41.5% during the first quarter. Deutsche Bank AG now owns 10,390 shares of the company’s stock worth $127,000 after purchasing an additional 3,048 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. Cantor Fitzgerald upped their price objective on CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, Canaccord Genuity Group boosted their price objective on shares of CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, CVRx currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.